Last edition
News about
Pandorum Technologies Raises USD 18 Million in Series B to Advance Regenerative Therapies
Pandorum Technologies has raised USD 18 million in a Series B funding round to accelerate the clinical development and global market access of its programmable tissue regenerative therapies, with expansion plans spanning the US, Asia and the Middle East.
China Grants Priority Review to Leqembi Subcutaneous BLA
The Priority Review and Approval Procedure has been implemented by the NMPA with the aim of accelerating research, development and launch of new medicines that have significant clinical value. Under this procedure, the assessment period is expected to be shortened.
Akums Receives First UK MHRA Approval for Rivaroxaban
Rivaroxaban is an oral anticoagulant prescribed for the prevention and treatment of thromboembolic disorders, including Non-Valvular Atrial Fibrillation (NVAF), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE) and clinically relevant cardiovascular risk reduction.
MerryLife Biomedical Reports Positive Phase I Data for Oral Alzheimer's Therapy TML-6
MerryLife Biomedical’s investigational oral therapy TML-6 demonstrated favourable safety and tolerability in Phase I, paving the way for a 210-patient global Phase II trial in early Alzheimer’s disease.
Innovent Biologics and Eli Lilly Forge Strategic Collaboration in Oncology and Immunology
Innovent Biologics will receive USD 350 million upfront and up to USD 8.5 billion in milestones under a new global development pact, with Lilly securing ex-Greater China rights to novel oncology and immunology programmes.
Roche's Fenebrutinib Matches Ocrevus in Slowing Disability Progression in PPMS Phase III Trial
Phase III FENtrepid study shows oral BTK inhibitor fenebrutinib achieved non-inferiority to Ocrevus in primary progressive multiple sclerosis, reducing disability progression risk by 12 percent with consistent subgroup benefit.
DIFF Biotech's Nasal Spray Influenza Vaccine Receives Clinical Trial Approval
As the first domestically self-developed nasal spray influenza vaccine in China to advance into clinical trial, DIFF-flu, manufactured by DIFF Biotech, leverages a pioneering M2 gene–modified attenuation technology, protected by multiple international invention patents.
SMC India partners with US-based AIRIA to deploy over 2,100 germicidal UVC systems in 116 high-risk TB hospitals, supporting India’s National TB Elimination Programme and strengthening airborne infection control.
Waters Completes Merger with BD's Biosciences and Diagnostic Solutions Businesses
Waters has completed its merger with BD’s Biosciences and Diagnostic Solutions businesses, creating a global life sciences and diagnostics leader focused on high-volume testing in regulated applications, alongside announcing the appointment of Claire M Fraser, PhD, to its Board and the formation of four new operating divisions.
Lilly’s acquisition of Orna Therapeutics aims to accelerate development of in vivo CAR-T therapies powered by engineered circular RNA and advanced lipid nanoparticle delivery platforms.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy